FOLFOX辅助化疗对中晚期老年直肠癌患者肿瘤标记物、免疫功能及生活质量的影响

The Influence of FOLFOX Adjuvant Chemotherapy on Tumor Markers,the Immune Function,and the Life Quality of Aged Patients with Middle-late Colorectal Cancer

目的探讨FOLFOX辅助化疗对中晚期直肠癌老年患者肿瘤标记物、免疫功能及生活质量的影响。方法选择2012年1月~2015年12月本院收治的中晚期直肠癌老年患者80例,按照随机数字法分为两组,各40例。观察组采用FOLFOX方案,对照组采用FOLFIRI方案,对所有入组者进行为期1年的门诊随访,比较两组干预前后CEA及CA-199水平变化情况、干预后体液免疫球蛋白水平、干预前后两组生活质量评分、临床疗效及1年生存情况。结果干预后两组CEA及CA-199水平显著低于干预前(P<0.05),且观察组显著低于对照组(P<0.05);干预后观察组Ig M、Ig G和Ig A水平均显著高于对照组(P<0.05);干预后两组生活质量评分显著优于干预前(P<0.05),且观察组显著优于对照组(P<0.05);观察组有效率显著高于对照组(P<0.05);观察组3月,6月及1年生存率均显著高于对照组(P<0.05)。结论 FOLFOX辅助化疗方案能有效降低患者肿瘤标记物水平,延长生存时间,提高免疫功能,改善生活质量。

Objective To explore the FOLFOX adjuvant chemotherapy on the immune function of aged middle-late colorectal tumor markers, and the influence of the quality of life. Methods 80 patients with advanced rectal cancer were divided into two groups from January 2012 to December 2012 in our hospital, 40 cases for each group. Patients in the observation group were given FOLFOX scheme, and those in the control group with FOLFIRI scheme. All patients had one year outpatient follow-up. The CEA and CA-199 level, the humoral immune globulin level after intervention, quality of life score, clinical effect, and 1-year survival situation of patients between the two groups were compared before and after the intervention. Results After intervention, CEA and CA-199 of patients were significantly lower than those be-fore intervention in the two groups （P〈0.05）. The CEA and CA-199 levels of patients in the observation group were significantly lower than in the control group after intervention （P〈0.05）. The postoperative IgM and IgG and IgA levels of patients in the observation group were higher than in the control group （P〈0.05）. Besides, the quality of life score of patients were better than that before in both groups after inter-vention （P〈0.05）. The quality of life of patients in the observation group was better than that in the control group after intervention （P〈0.05）. The effectiveness of patients in the observation group was significantly higher than that in the control group （P〈0.05）. The 3 months, 6 months and 1 year survival rates of patients in the observation group were also significantly higher than that in the control group. Conclu-sion FOLFOX middle-late adjuvant chemotherapy regimen for patients with rectal cancer, brain function effectively reduces the body tumor marker levels, improves immune ability, the quality of life, the effect of clinical treatment, and the survival time.